Ever since Insulet launched the Omnipod five years ago, the patch pump has been gaining steam as the must-have gadget for diabetes device companies. Many companies are in the works developing (or acquiring the technology to develop) their own, from market leaders Medtronic to newcomers like Debiotech with their Jewel pump. Now another company out of London, Cellnovo, is making its way on the scene, and getting some very hot press… but how good is…Read more »
This week, J&J’s Animas is recalling a batch of 45,000 faulty insulin cartridges shipped between Nov. 30, 2010, and Jan. 4, 2011, that reportedly can leak insulin, resulting in the delivery of less insulin than intended. Note that the pump most likely will not alarm if there is an internal leak. If you are affected by this, you should be receiving an email and a letter from the company shortly, in addition to a set…Read more »
Speaking of iPhone-ish diabetes devices (aren’t we always?), a number of readers asked us lately for an update on the new Tandem insulin pump, which could hardly look more Apple’esque if it tried:
The San Diego-based company has been developing this one for several years, and recently added some famous names to its Clinical Advisory Board: insulin pump experts Dr. Bruce Bode, CDEs Virginia Valentine and John Walsch, and Dr. Steven Edelman of TCOYD fame.…Read more »
I can’t help it. This reminds me of the movie City Slickers, in which one of the characters has messed up his life, and his friends tell him he’s getting a “do-over.” The young company Dance Pharmaceuticals, based in downtown San Francisco, is basically on a mission to salvage the good parts of Pfizer’s failed inhaled insulin Exubera (not the awkward delivery device!) and launch a second coming of the base product that is “simpler,…Read more »
Happy New Year, everyone! I’ve been mostly off-line this past week, attempting to enjoy the “break” while cleaning and sorting out our fresh-from-construction home. But even in that daze, I couldn’t help noticing all the fuss about MannKind’s Afrezza, which was supposed to be ruled upon by the FDA on Dec. 29.
The FDA has requested an additional four weeks to make a decision on this new inhalable insulin, after having postponed the decision by…